The comparison of effectiveness between intravenous and subcutaneous administration route of tocilizumab in patients with rheumatoid arthritis

The comparison of effectiveness between intravenous and subcutaneous administration route of tocilizumab in patients with rheumatoid arthritis - The comparison of effectiveness between intravenous and subcutaneous administration route of tocilizumab in patients with rheumatoid arthritis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028261

Enrollment

100

Registered

2017-07-17

Start date

2017-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: RA patients fulling the American Rheumatology Association criteria 1987 and ACR/EULAR classification cliteria 2010. The patients started tocilizumab therapy.

Exclusion criteria

Exclusion criteria: Patients with other diseases that can affect the infllamation state. Patients who was deemed inappropriate by test doctor to participate in this study.

Design outcomes

Primary

Measure	Time frame
The comparison of ultrasonographic findings between intravenus and subcutaneous administration route of tocilizumab	—

Countries

Japan

Contacts

Public ContactTadashi Okano

Osaka City University Medical School Orthopedic Surgery

ma1sa3ru@med.osaka-cu.ac.jp0666453851

Outcome results